Amit C. Nathwani

Amit C. Nathwani

Auto-generated profile, based on publicly available information

Amit C. Nathwani

Haematology Department, Cancer Institute, University College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2025 in Blood
Verified
Journal Article
Closed access
VMVincent Muczynski
Vincent Muczynski
OCOlivier Christophe
Olivier Christophe
LTLewis Tanner
Lewis Tanner
CVCharlotte Vayssiere
Charlotte Vayssiere
AGAlice Guérin
Alice Guérin
ANAmit C. Nathwani
Amit C. Nathwani
The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.

5 July 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
KEKurtis Edwards
Kurtis Edwards
KZKristina Zaitseva
Kristina Zaitseva
USUzma Sayed
Uzma Sayed
EVEmanuela V. Volpi
Emanuela V. Volpi
ANAmit Nathwani
Amit Nathwani
NPNino Porakishvili
Nino Porakishvili
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.